Stocks | | |
Finding good stocks to buy in the market these days is no easy task. Although stocks have rebounded nicely off of the March lows, many investors are having trouble figuring out why. Some even believe that we have never seen such a large disconnect between equity valuations and fundamentals. Even b... Read the Full Story |
|
From Our PartnersREVEALED: $194 Trillion Trump Market Pattern
Trump fires off a tweet and stocks tank…
He gives a speech and the markets soar…
Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets.
And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance. | | | Click here to discover this exciting new trading pattern. |
|
Markets | | | It's been amazing to witness the way that technology has changed how businesses operate over the last decade.Twilio Inc (NYSE:TWLO) is a cloud communications platform that essentially helps companies add voice, messaging, and video capabilities Read the Full Story |
|
Markets | | |
Latin America is a region of the world that seems to be a little late to the party in terms of adapting e-commerce into their everyday life. However, that seems to be changing fast thanks to MercadoLibre (NASDAQ:MELI), which is a rapidly growing online commerce and payments business. The company r... Read the Full Story |
|
|
Markets | | |
As volatile as the stock market has been for the last couple of months now, the cryptocurrency market has been that volatile for years now. Bitcoin, pretty much the gold standard in cryptocurrency, has seen wild changes in valuation just in the last year. The price over the last year retested the ... Read the Full Story |
|
Markets | | |
On Friday, May 8 Kimco Realty (NYSE:KIM) posted a positive first-quarter earnings report. For a real estate investment trust (REIT), the quarterly funds from operation (FFO) is a critical metric. And Kimco delivered FFO of 37 cents per share. This beat analysts’ estimates for 36 cents per sh... Read the Full Story |
|
From Our PartnersBehind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented.
And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots…
What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book. | | | Claim your FREE copy of Crypto Revolution now. |
|
The Early Bird Stock Of The Day VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
